The PLASMIC Score was developed by Bendapudi and colleagues at Massachusetts General Hospital in 2017 from a derivation cohort of 112 patients with thrombotic microangiopathy (TMA), then externally validated in 63 patients. It was designed to rapidly identify patients with severe ADAMTS13 deficiency (the hallmark of thrombotic thrombocytopenic purpura) before ADAMTS13 results return — which typically takes 2-5 days. Given that TTP mortality without plasma exchange exceeds 90%, earlier identification and treatment is life-saving. The seven PLASMIC criteria can be evaluated at the bedside from routine blood tests available within hours of presentation.